Medtronic Gets To Heart Of Cell Therapy Through Genzyme Collaboration
This article was originally published in The Gray Sheet
Executive Summary
Medtronic will draw on expertise from its three cardiac-related divisions to aid Genzyme in the development of a catheter-delivered cell therapy for cardiovascular disease
You may also be interested in...
Cordis/Advanced Cell Technology
The Biologics Delivery Systems group of Johnson & Johnson/Cordis will supply catheters for administering Advanced Cell Technology's stem cell therapy for treatment of heart failure in a Phase II clinical trial, ACT announces March 5. The myoblast therapy involves transplanting stem cells derived from a patient's leg muscle into scarred heart tissue to help rebuild the heart muscle and prevent progression of congestive heart failure. The trial will use the Cordis group's NOGA cardiac navigation system and MyoStar injection catheter. Medtronic and Genzyme are also collaborating on catheter delivery of myoblast treatment (1"The Gray Sheet" June 7, 2004, p. 13)
Cordis/Advanced Cell Technology
The Biologics Delivery Systems group of Johnson & Johnson/Cordis will supply catheters for administering Advanced Cell Technology's stem cell therapy for treatment of heart failure in a Phase II clinical trial, ACT announces March 5. The myoblast therapy involves transplanting stem cells derived from a patient's leg muscle into scarred heart tissue to help rebuild the heart muscle and prevent progression of congestive heart failure. The trial will use the Cordis group's NOGA cardiac navigation system and MyoStar injection catheter. Medtronic and Genzyme are also collaborating on catheter delivery of myoblast treatment (1"The Gray Sheet" June 7, 2004, p. 13)
Medtronic Continues To Run (RNA) Interference With Biotech Firm Alnylam
Medtronic is upping its investment in biotech drug delivery by expanding its collaboration with Alnylam for development of an RNA-based treatment for Huntington's disease